ICYMI: Farmingdale-Based Codagenix Testing Coronavirus Vaccine

FARMINGDALE, NY — Codagenix, a biotechnology firm based at the Broad Hollow Bioscience Park of Farmingdale State College, said it recently began testing its coronavirus vaccine candidate on people.

The firm and the Serum Institute of India said they launched a phase 1 trial involving 48 volunteers who will be administered three dosage levels to determine the vaccine's safety. Data from the trial is expected by mid-2021 and advanced clinical testing could begin soon after. If all goes well, the Codagenix vaccine could hit the market in 2022, according to a representative.

The first patient was given the vaccine, called COVI-VAC, last week. Codagenix CEO J. Robert Coleman said it was an important milestone, and he believes his company's vaccine has "significant" advantages over other coronavirus immunizations.

Click here to read the full story.